Assessment of serum-matrix metalloproteinases MMP-2 and MMP-9 after human liver transplantation: Increased serum MMP-9 level in acute rejection

Transplantation

Volumn 77, Issue 11, 2004, Pages 1646-1652

  Kuyvenhoven, Johan Ph ^a   Verspaget, Hein W ^a   Gao, Qiang ^a   Ringers, Jan ^a   Smit, Vincent T H B M ^a   Lamers, Cornelis B H W ^a   Van Hoek, Bart ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME MECHANISM; ENZYME SYNTHESIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN DETERMINATION;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; GRAFT REJECTION; HEPATITIS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; POSTOPERATIVE PERIOD; STAINING AND LABELING;

EID: 2942676955     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000131170.67671.75     Document Type: Article

References (30)

1. Neuberger J. Incidence, timing, and risk factors for acute and chronic rejection. Liver Transpl Surg 1999; 5: S30.
2. Banffschema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25: 658.
3. Shapiro SD. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr Opin Cell Biol 1998; 10: 602.
4. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491.
5. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463.
6. Arthur MJ. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2000; 279: G245.
7. Upadhya AG, Harvey RP, Howard TK, et al. Evidence of a role for matrix metalloproteinases in cold preservation injury of the liver in humans and in the rat. Hepatology 1997; 26: 922.
8. Kuyvenhoven JP, Hoek B van, Blom E, et al. Assessment of the clinical significance of serum matrix metalloproteinases MMP-2 and MMP-9 in patients with various liver diseases and hepatocellular carcinoma. Thromb Haemost 2003; 4: 718.
9. Vierling JM. Immunology of acute and chronic hepatic allograft rejection. Liver Transpl Surg 1999; 5: S1.
10. Bumgardner GL, Orosz CG. Transplantation and cytokines. Semin Liver Dis 1999; 19: 189.
11. Mueller AR, Platz KP, Gebauer B, et al. Changes at the extracellular matrix during acute and chronic rejection in human liver transplantation. Transpl Int 1998; 11(Suppl 1): S377.
12. Gveric D, Hanemaaijer R, Newcombe J, et al. Plasminogen activators in multiple sclerosis lesions: implications for the inflammatory response and axonal damage. Brain 2001; 124: 1978.
13. Sier CF, Casetta G, Verheijen JH, et al. Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with earlystage bladder carcinoma: a comparison with clinically used tumor markers. Clin Cancer Res 2000; 6: 2333.
14. Capper SJ, Verheijen J, Smith L, et al. Determination of gelatinase-A (MMP-2) activity using a novel immunocapture assay. Ann N Y Acad Sci 1999; 878: 487.
15. Sier CF, Vloedgraven HJ, Ganesh S, et al. Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. Gastroenterology 1994; 107: 1449.
16. Milani S, Herbst H, Schuppan D, et al. Differential expression of matrix-metalloproteinase-1 and -2 genes in normal and fibrotic human liver. Am J Pathol 1994; 144: 528-537.
17. Preaux AM, Mallat A, Nhieu JT, et al. Matrix metalloproteinase-2 activation in human hepatic fibrosis regulation by cell-matrix interactions. Hepatology 1999; 30: 944.
18. Murawaki Y, Yamada S, Ikuta Y, et al. Clinical usefulness of serum matrix metalloproteinase-2 concentration in patients with chronic viral liver disease. J Hepatol 1999; 30: 1090.
19. Mueller AR, Platz KP, Schumacher G, et al. Mechanisms of preservation and reperfusion injury in human liver transplantation. Transplant Proc 1997; 29: 3455.
20. Ebata M, Fukuda Y, Nakano I, et al. Serum levels of tissue inhibitor of metalloproteinases-2 and of precursor form of matrix metalloproteinase-2 in patients with liver disease. Liver 1997; 17: 293.
21. Demirci G, Hoshino K, Nashan B. Expression patterns of integrin receptors and extracellular matrix proteins in chronic rejection of human liver allografts. Transpl Immunol 1999; 7: 229.
22. Rodrigo E, Lopez-Hoyos M, Escallada R, et al. Circulating levels of matrix metalloproteinases MMP-3 and MMP-2 in renal transplant recipients with chronic transplant nephropathy. Nephrol Dial Transplant 2000; 15: 2041.
23. Mueller AR, Platz KP, Heckert C, et al. The extracellular matrix: an early target of preservation/reperfusion injury and acute rejection after small bowel transplantation. Transplantation 1998; 65: 770.
24. Kimizuka K, Fujisaki S, Park Y, et al. Immunohistochemical changes in matrix metalloproteinase-2 and 9 during small bowel allograft rejection in rats. Transplant Proc 2002; 34: 1047.
25. Suzuki J, Isobe M, Kawauchi M, et al. Altered expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in acutely rejected myocardium and coronary arteriosclerosis in cardiac allografts of nonhuman primates. Transpl Int 2000; 13: 106.
26. Benyon RC, Arthur MJ. Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis 2001; 21: 373.
27. Goetzl EJ, Banda MJ, Leppert D. Matrix metalloproteinases in immunity. J Immunol 1996; 156: 1.
28. Opdenakker G, Van den Steen PE, Dubois B, et al. Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol 2001; 69: 851.
29. Lindsey M, Wedin K, Brown MD, et al. Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation 2001; 103: 2181.
30. Baugh MD, Perry MJ, Hollander AP, et al. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 1999; 117: 814.